Clinical Trials Browser

OTHER × Pancreatic Ductal Adenocarcinoma × irinotecan sucrosofate × Clear all

NCT06467565 2024-06-21

NALIRIFOX as Induction Therapy in LAPC

Phase 2 Recruiting

Gastrointestinal

Pancreatic Ductal Adenocarcinoma